52.13
5.90%
-3.27
After Hours:
52.14
0.010
+0.02%
Enovis Corp stock is currently priced at $52.13, with a 24-hour trading volume of 1.65M.
It has seen a -5.90% decreased in the last 24 hours and a -13.58% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $55.43 pivot point. If it approaches the $52.47 support level, significant changes may occur.
Previous Close:
$55.40
Open:
$53.46
24h Volume:
1.65M
Market Cap:
$2.86B
Revenue:
$1.71B
Net Income/Loss:
$-33.26M
P/E Ratio:
-20.44
EPS:
-2.55
Net Cash Flow:
$12.77M
1W Performance:
-5.39%
1M Performance:
-13.58%
6M Performance:
+13.15%
1Y Performance:
-10.17%
Enovis Corp Stock (ENOV) Company Profile
Name
Enovis Corp
Sector
Industry
Phone
302 252 9190
Address
2711 Centerville Road, Suite 400, Wilmington
Enovis Corp Stock (ENOV) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-13-24 | Initiated | Stephens | Overweight |
Jan-22-24 | Initiated | UBS | Buy |
Jan-03-24 | Initiated | William Blair | Outperform |
Dec-15-23 | Reiterated | Needham | Buy |
Oct-20-23 | Initiated | ROTH MKM | Buy |
Jun-26-23 | Initiated | Needham | Buy |
May-12-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Oct-12-22 | Initiated | Jefferies | Buy |
Oct-11-22 | Initiated | Goldman | Buy |
Sep-12-22 | Initiated | Canaccord Genuity | Buy |
Sep-12-22 | Initiated | Evercore ISI | Outperform |
Jun-28-22 | Initiated | Argus | Hold |
Jun-27-22 | Resumed | Loop Capital | Buy |
Jun-16-22 | Initiated | Wells Fargo | Equal Weight |
View All
Enovis Corp Stock (ENOV) Latest News
Enovis (ENOV) Q1 Earnings Match Estimates
Zacks Investment Research
Enovis Announces First Quarter 2024 Results
GlobeNewswire Inc.
Enovis to Host First Quarter 2024 Results Conference Call on May 2nd
GlobeNewswire Inc.
Medtech Firm Enovis Sets Strong 2024 Targets As Q4 Earnings Beat Expectations, Analyst Says Growth Intact
Benzinga
Enovis Announces Fourth Quarter and Full Year 2023 Results
GlobeNewswire Inc.
Biotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
Enovis Corp Stock (ENOV) Financials Data
Enovis Corp (ENOV) Revenue 2024
ENOV reported a revenue (TTM) of $1.71 billion for the quarter ending December 31, 2023, a +9.22% rise year-over-year.
Enovis Corp (ENOV) Net Income 2024
ENOV net income (TTM) was -$33.26 million for the quarter ending December 31, 2023, a -150.23% decrease year-over-year.
Enovis Corp (ENOV) Cash Flow 2024
ENOV recorded a free cash flow (TTM) of $12.77 million for the quarter ending December 31, 2023, a +107.91% increase year-over-year.
Enovis Corp (ENOV) Earnings per Share 2024
ENOV earnings per share (TTM) was -$0.61 for the quarter ending December 31, 2023, a -144.00% decline year-over-year.
About Enovis Corp
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Cap:
|
Volume (24h):